Velosulin

RSS

Withdrawn

This medicine's authorisation has been withdrawn

insulin human (rDNA)
MedicineHumanWithdrawn

Polish is available via eTranslation, the European Commission's machine translation service.

Translate to Polish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 7 October 2002, the European Commission granted a marketing authorisation valid throughout the European Union for the medicinal product Velosulin (insulin human) 10ml (3.5 mg/ml) for subcutaneous or intravenous use, indicated for the treatment of diabetes mellitus.

On 18 December 2008, the marketing authorisation holder (MAH) responsible for Velosulin, Novo Nordisk A/S, notified the European Commission of its decision to voluntarily withdraw its marketing authorisation for commercial reasons.

On 30 January 2009, the European Commission issued a decision to withdraw the marketing authorisation for Velosulin. Pursuant to this decision, the European Public Assessment Report for Velosulin is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (452.11 KB - PDF)

Zobacz

español (ES) (251.23 KB - PDF)

Zobacz

čeština (CS) (388.11 KB - PDF)

Zobacz

dansk (DA) (251.1 KB - PDF)

Zobacz

Deutsch (DE) (251.99 KB - PDF)

Zobacz

eesti (ET) (248.8 KB - PDF)

Zobacz

ελληνικά (EL) (409.39 KB - PDF)

Zobacz

français (FR) (252.31 KB - PDF)

Zobacz

italiano (IT) (251.04 KB - PDF)

Zobacz

latviešu (LV) (392.34 KB - PDF)

Zobacz

lietuvių (LT) (362.9 KB - PDF)

Zobacz

magyar (HU) (380.34 KB - PDF)

Zobacz

Malti (MT) (403.22 KB - PDF)

Zobacz

Nederlands (NL) (251.47 KB - PDF)

Zobacz

polski (PL) (396.48 KB - PDF)

Zobacz

português (PT) (251.67 KB - PDF)

Zobacz

română (RO) (369.22 KB - PDF)

Zobacz

slovenčina (SK) (383.24 KB - PDF)

Zobacz

slovenščina (SL) (376.6 KB - PDF)

Zobacz

suomi (FI) (250.33 KB - PDF)

Zobacz

svenska (SV) (250.99 KB - PDF)

Zobacz

Product information

български (BG) (738.17 KB - PDF)

Zobacz

español (ES) (593.05 KB - PDF)

Zobacz

čeština (CS) (672.87 KB - PDF)

Zobacz

dansk (DA) (571.96 KB - PDF)

Zobacz

Deutsch (DE) (605.75 KB - PDF)

Zobacz

eesti (ET) (567.03 KB - PDF)

Zobacz

ελληνικά (EL) (740.04 KB - PDF)

Zobacz

français (FR) (594.89 KB - PDF)

Zobacz

italiano (IT) (568.84 KB - PDF)

Zobacz

latviešu (LV) (808.55 KB - PDF)

Zobacz

lietuvių (LT) (683.46 KB - PDF)

Zobacz

magyar (HU) (669.7 KB - PDF)

Zobacz

Malti (MT) (664.95 KB - PDF)

Zobacz

Nederlands (NL) (556.67 KB - PDF)

Zobacz

polski (PL) (695.57 KB - PDF)

Zobacz

português (PT) (586.37 KB - PDF)

Zobacz

română (RO) (666.25 KB - PDF)

Zobacz

slovenčina (SK) (702.27 KB - PDF)

Zobacz

slovenščina (SL) (645.56 KB - PDF)

Zobacz

suomi (FI) (579.74 KB - PDF)

Zobacz

svenska (SV) (576.07 KB - PDF)

Zobacz
Latest procedure affecting product information:N/0007
16/03/2008
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (330.79 KB - PDF)

Zobacz

español (ES) (273.45 KB - PDF)

Zobacz

čeština (CS) (316.83 KB - PDF)

Zobacz

dansk (DA) (276.68 KB - PDF)

Zobacz

Deutsch (DE) (278.91 KB - PDF)

Zobacz

eesti (ET) (272.33 KB - PDF)

Zobacz

ελληνικά (EL) (323.13 KB - PDF)

Zobacz

français (FR) (273.33 KB - PDF)

Zobacz

italiano (IT) (272.07 KB - PDF)

Zobacz

latviešu (LV) (315.75 KB - PDF)

Zobacz

lietuvių (LT) (294.91 KB - PDF)

Zobacz

magyar (HU) (317.63 KB - PDF)

Zobacz

Malti (MT) (324.78 KB - PDF)

Zobacz

Nederlands (NL) (273.43 KB - PDF)

Zobacz

polski (PL) (318.74 KB - PDF)

Zobacz

português (PT) (274.38 KB - PDF)

Zobacz

română (RO) (297.98 KB - PDF)

Zobacz

slovenčina (SK) (318.32 KB - PDF)

Zobacz

slovenščina (SL) (302.9 KB - PDF)

Zobacz

suomi (FI) (270.99 KB - PDF)

Zobacz

svenska (SV) (274.74 KB - PDF)

Zobacz

Product details

Name of medicine
Velosulin
Active substance
insulin human
International non-proprietary name (INN) or common name
insulin human (rDNA)
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
A10AB01

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Treatment of diabetes mellitus.

Authorisation details

EMA product number
EMEA/H/C/000423
Marketing authorisation holder
Novo Nordisk A/S

Novo Allé
DK-2880 Bagsvaerd
Denmark

Marketing authorisation issued
07/10/2002
Withdrawal of marketing authorisation
30/01/2009
Revision
5

Assessment history

This page was last updated on

Share this page